Initium Therapeutics was established to develop innovative antibody-based therapeutics, including pursuing new therapeutic targets in fibrosis, immuno-oncology and hemophilia. Initium was established in June of 2020 as a spin-off of South Korea-based Tiumbio in order to expand its capability to antibody drug development platforms.
Initium says that using its unique antibody development platforms of DNA immunization technology and AbCassette-High express system it generates more diverse antigen-specific B cell repertoire and expedites screening of functional therapeutic antibodies, which mostly recognize very challenging small and complex conformational epitopes of membrane associated protein targets such as GPCRs (G protein coupled receptors), to treat unaddressed rare diseases.
Initium recently announced a strategic collaboration with GenScript ProBio, in which Initium plans to utilize GenScript ProBio’s Berkeley Lights Beacon Platform to expand its antibody drug pipeline.
- Archon BiosciencesArchon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to… Read more: Archon Biosciences
- Cytospire TherapeuticsFounded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune… Read more: Cytospire Therapeutics
- This Week in Biotech Venture CapitalThe biotech sector continues to see a strong flow of new venture… Read more: This Week in Biotech Venture Capital
- THRONCATTHRONCAT is a new startup that aims to transform the field of… Read more: THRONCAT
- Roundup of recent venture funding roundsThe biotechnology sector is advancing rapidly, fueled by significant venture capital investments… Read more: Roundup of recent venture funding rounds
- Analona TherapeuticsFounded in 2024, Analona Therapeutics is a biotech company located in Denmark… Read more: Analona Therapeutics